dc.date.accessioned | 2023-02-22T19:15:04Z | |
dc.date.available | 2023-02-22T19:15:04Z | |
dc.date.created | 2022-12-25T11:29:03Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Røssevold, Andreas Hagen Andresen, Nikolai Kragøe Bjerre, Christina Annette Gilje, Bjørnar Jakobsen, Erik Hugger Raj, Sunil Xavier Falk, Ragnhild Sørum Russnes, Hege Elisabeth Giercksky Jahr, Thea Ruud, Randi Margit Lømo, Jon Garred, Øystein Chauhan, Sudhir Kumar Lereim, Ragnhild Reehorst Dunn, Claire Naume, Bjørn Kyte, Jon A . Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. Nature Medicine. 2022, 1-28 | |
dc.identifier.uri | http://hdl.handle.net/10852/100384 | |
dc.description.abstract | Immune checkpoint inhibitors have shown efficacy against metastatic triple-negative breast cancer (mTNBC) but only for PD-L1positive disease. The randomized, placebo-controlled ALICE trial (NCT03164993, 24 May 2017) evaluated the addition of atezolizumab (anti-PD-L1) to immune-stimulating chemotherapy in mTNBC. Patients received pegylated liposomal doxorubicin (PLD) and low-dose cyclophosphamide in combination with atezolizumab (atezo-chemo; n = 40) or placebo (placebo-chemo; n = 28). Primary endpoints were descriptive assessment of progression-free survival in the per-protocol population (>3 atezolizumab and >2 PLD doses; n = 59) and safety in the full analysis set (FAS; all patients starting therapy; n = 68). Adverse events leading to drug discontinuation occurred in 18% of patients in the atezo-chemo arm (7/40) and in 7% of patients in the placebo-chemo arm (2/28). Improvement in progression-free survival was indicated in the atezo-chemo arm in the per-protocol population (median 4.3 months versus 3.5 months; hazard ratio (HR) = 0.57; 95% confidence interval (CI) 0.33–0.99; log-rank P = 0.047) and in the FAS (HR = 0.56; 95% CI 0.33–0.95; P = 0.033). A numerical advantage was observed for both the PD-L1positive (n = 27; HR = 0.65; 95% CI 0.27–1.54) and PD-L1negative subgroups (n = 31; HR = 0.57, 95% CI 0.27–1.21). The progression-free proportion after 15 months was 14.7% (5/34; 95% CI 6.4–30.1%) in the atezo-chemo arm versus 0% in the placebo-chemo arm. The addition of atezolizumab to PLD/cyclophosphamide was tolerable with an indication of clinical benefit, and the findings warrant further investigation of PD1/PD-L1 blockers in combination with immunomodulatory chemotherapy. | |
dc.language | EN | |
dc.publisher | Nature Portfolio | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial | |
dc.title.alternative | ENEngelskEnglishAtezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial | |
dc.type | Journal article | |
dc.creator.author | Røssevold, Andreas Hagen | |
dc.creator.author | Andresen, Nikolai Kragøe | |
dc.creator.author | Bjerre, Christina Annette | |
dc.creator.author | Gilje, Bjørnar | |
dc.creator.author | Jakobsen, Erik Hugger | |
dc.creator.author | Raj, Sunil Xavier | |
dc.creator.author | Falk, Ragnhild Sørum | |
dc.creator.author | Russnes, Hege Elisabeth Giercksky | |
dc.creator.author | Jahr, Thea | |
dc.creator.author | Ruud, Randi Margit | |
dc.creator.author | Lømo, Jon | |
dc.creator.author | Garred, Øystein | |
dc.creator.author | Chauhan, Sudhir Kumar | |
dc.creator.author | Lereim, Ragnhild Reehorst | |
dc.creator.author | Dunn, Claire | |
dc.creator.author | Naume, Bjørn | |
dc.creator.author | Kyte, Jon A | |
cristin.unitcode | 185,53,49,10 | |
cristin.unitname | Avdeling for kreftbehandling | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |
dc.identifier.cristin | 2097357 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Nature Medicine&rft.volume=&rft.spage=1&rft.date=2022 | |
dc.identifier.jtitle | Nature Medicine | |
dc.identifier.volume | 28 | |
dc.identifier.issue | 12 | |
dc.identifier.startpage | 2573 | |
dc.identifier.endpage | 2583 | |
dc.identifier.doi | https://doi.org/10.1038/s41591-022-02126-1 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1078-8956 | |
dc.type.version | PublishedVersion | |